The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - medimmune
Phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in myelodysplastic syndrome (MDS) after treatment with hypomethylating agents.
 
Guillermo Garcia-Manero
Research Funding - medimmune (Inst)
 
Charles Alan Schiffer
Consulting or Advisory Role - Ambit BioSciences; Celgene; Novartis; PFIZER; TAKEDA; TEVA
Research Funding - NOVARTIS, BMS, CELGENE, ARIAD (Inst)
 
Lucy A. Godley
Honoraria - Agios
 
Ronald Paquette
Research Funding - MedImmune (Inst)
 
Uwe Platzbecker
No Relationships to Disclose
 
Paul B. Robbins
Employment - MedImmune
Stock and Other Ownership Interests - AstraZeneca
 
Jonathan Norton
Employment - medimmune
Stock and Other Ownership Interests - medimmune
Research Funding - medimmune (Inst)
 
Joyson Joseph Karakunnel
Employment - MedImmune; Suburban Hosptial
Research Funding - MedImmune
Patents, Royalties, Other Intellectual Property - medimmune
Travel, Accommodations, Expenses - MedImmune
Other Relationship - medimmune
 
Robert Coleman Lindsley
Research Funding - medimmune (Inst)